A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

NCT07358676 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)
SCLC, Extensive Stage

Interventions

COMBINATION_PRODUCT: Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital